{"transactions":[{"id":4635457,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:12:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":31908,"price":27.021,"value":862186.068,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.585 to $27.47 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":191447,"source":{"system":"sec-edgar","filing":"0001676170-26-000024","document":"form4-10022026_081010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000024/form4-10022026_081010.xml","form_type":"4"}},{"id":4635456,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T00:12:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2593,"price":27.0241,"value":70073.4913,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.645 to $27.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":15558,"source":{"system":"sec-edgar","filing":"0001676170-26-000024","document":"form4-10022026_081010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000024/form4-10022026_081010.xml","form_type":"4"}},{"id":4634135,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T00:09:58.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":16141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":144521,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":16141},"source":{"system":"sec-edgar","filing":"0002050172-26-000038","document":"form4-10022026_081053.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000038/form4-10022026_081053.xml","form_type":"4"}},{"id":4634134,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-10-03T00:09:58.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":16141,"price":26.9341,"value":434743.3081,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.47 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000038","document":"form4-10022026_081053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000038/form4-10022026_081053.xml","form_type":"4"}},{"id":4634133,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-10-03T00:09:58.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":16141,"price":10.42,"value":168189.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":16141,"source":{"system":"sec-edgar","filing":"0002050172-26-000038","document":"form4-10022026_081053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000038/form4-10022026_081053.xml","form_type":"4"}},{"id":4634140,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T00:06:59.000Z","date":"2026-09-29","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025."}],"balance_after":6643,"derivative":{"exercise_price":10.42,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0002050167-26-000030","document":"form4-10012026_081054.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000030/form4-10012026_081054.xml","form_type":"4"}},{"id":4634139,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-10-02T00:06:59.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":27.0561,"value":202920.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32316,"source":{"system":"sec-edgar","filing":"0002050167-26-000030","document":"form4-10012026_081054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000030/form4-10012026_081054.xml","form_type":"4"}},{"id":4634138,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-10-02T00:06:59.000Z","date":"2026-09-29","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":10.42,"value":78150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":39816,"source":{"system":"sec-edgar","filing":"0002050167-26-000030","document":"form4-10012026_081054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000030/form4-10012026_081054.xml","form_type":"4"}},{"id":3520894,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-08T20:20:35.000Z","date":"2026-09-04","kind":"sale","planned":true,"acquired":false,"shares":9705,"price":26.2238,"value":254501.979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.42 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000036","document":"form4-09082026_080930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000036/form4-09082026_080930.xml","form_type":"4"}},{"id":4540,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1856,"kind":"person","name":"Courtney Phillips","position":1,"cik":"0001782758","reported_name":"Courtney Phillips","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC and Corp. Secretary"}}],"security":"Common Stock","published_at":"2026-09-04T20:27:14.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":22,"price":25.78,"value":567.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."}],"balance_after":7007,"source":{"system":"sec-edgar","filing":"0001782758-26-000008","document":"form4-09042026_080910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000178275826000008/form4-09042026_080910.xml","form_type":"4"}},{"id":4539,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1856,"kind":"person","name":"Courtney Phillips","position":1,"cik":"0001782758","reported_name":"Courtney Phillips","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC and Corp. Secretary"}}],"security":"Common Stock","published_at":"2026-09-04T20:27:14.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":1990,"price":26.0133,"value":51766.467,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive."}],"balance_after":7029,"source":{"system":"sec-edgar","filing":"0001782758-26-000008","document":"form4-09042026_080910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000178275826000008/form4-09042026_080910.xml","form_type":"4"}},{"id":4538,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1856,"kind":"person","name":"Courtney Phillips","position":1,"cik":"0001782758","reported_name":"Courtney Phillips","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC and Corp. Secretary"}}],"security":"Common Stock","published_at":"2026-09-04T20:27:14.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":243,"price":27.1211,"value":6590.4273,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive."}],"balance_after":9019,"source":{"system":"sec-edgar","filing":"0001782758-26-000008","document":"form4-09042026_080910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000178275826000008/form4-09042026_080910.xml","form_type":"4"}},{"id":4537,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1856,"kind":"person","name":"Courtney Phillips","position":1,"cik":"0001782758","reported_name":"Courtney Phillips","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC and Corp. Secretary"}}],"security":"Common Stock","published_at":"2026-09-04T20:27:14.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":1738,"price":26.376,"value":45841.488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":9262,"source":{"system":"sec-edgar","filing":"0001782758-26-000008","document":"form4-09042026_080910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000178275826000008/form4-09042026_080910.xml","form_type":"4"}},{"id":4518,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-09-04T20:25:49.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":36,"price":25.81,"value":929.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."}],"balance_after":32316,"source":{"system":"sec-edgar","filing":"0002050167-26-000027","document":"form4-09042026_080945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000027/form4-09042026_080945.xml","form_type":"4"}},{"id":4517,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-09-04T20:25:49.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":3207,"price":26.0133,"value":83424.6531,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive."}],"balance_after":32352,"source":{"system":"sec-edgar","filing":"0002050167-26-000027","document":"form4-09042026_080945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000027/form4-09042026_080945.xml","form_type":"4"}},{"id":4516,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-09-04T20:25:49.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":391,"price":27.1211,"value":10604.3501,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive."}],"balance_after":35559,"source":{"system":"sec-edgar","filing":"0002050167-26-000027","document":"form4-09042026_080945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000027/form4-09042026_080945.xml","form_type":"4"}},{"id":4515,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-09-04T20:25:49.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":2800,"price":26.376,"value":73852.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":35950,"source":{"system":"sec-edgar","filing":"0002050167-26-000027","document":"form4-09042026_080945.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000027/form4-09042026_080945.xml","form_type":"4"}},{"id":4506,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:24:27.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":129,"price":25.7749,"value":3324.9621,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."}],"balance_after":27362,"source":{"system":"sec-edgar","filing":"0001676170-26-000022","document":"form4-09042026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000022/form4-09042026_080923.xml","form_type":"4"}},{"id":4505,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:24:27.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":11282,"price":26.0133,"value":293482.0506,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive."}],"balance_after":27491,"source":{"system":"sec-edgar","filing":"0001676170-26-000022","document":"form4-09042026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000022/form4-09042026_080923.xml","form_type":"4"}},{"id":4504,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:24:27.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":1375,"price":27.1211,"value":37291.5125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive."}],"balance_after":38773,"source":{"system":"sec-edgar","filing":"0001676170-26-000022","document":"form4-09042026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000022/form4-09042026_080923.xml","form_type":"4"}},{"id":4503,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:24:27.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":9852,"price":26.376,"value":259856.352,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":40148,"source":{"system":"sec-edgar","filing":"0001676170-26-000022","document":"form4-09042026_080923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000022/form4-09042026_080923.xml","form_type":"4"}},{"id":4497,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":59,"price":25.78,"value":1521.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."}],"balance_after":9705,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":4496,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":5130,"price":26.0133,"value":133448.229,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive."}],"balance_after":9764,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":4495,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":625,"price":27.1211,"value":16950.6875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive."}],"balance_after":14894,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":4494,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-04T20:22:03.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":4481,"price":26.376,"value":118190.856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":15519,"source":{"system":"sec-edgar","filing":"0002050172-26-000034","document":"form4-09042026_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000034/form4-09042026_080958.xml","form_type":"4"}},{"id":2468,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1856,"kind":"person","name":"Courtney Phillips","position":1,"cik":"0001782758","reported_name":"Courtney Phillips","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC and Corp. Secretary"}}],"security":"Restricted Stock Units","published_at":"2026-09-03T20:31:00.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":11000,"derivative":{"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001782758-26-000006","document":"form4-09032026_080954.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000178275826000006/form4-09032026_080954.xml","form_type":"4"}},{"id":2467,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1856,"kind":"person","name":"Courtney Phillips","position":1,"cik":"0001782758","reported_name":"Courtney Phillips","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC and Corp. Secretary"}}],"security":"Common Stock","published_at":"2026-09-03T20:31:00.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001782758-26-000006","document":"form4-09032026_080954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000178275826000006/form4-09032026_080954.xml","form_type":"4"}},{"id":2426,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Restricted Stock Units","published_at":"2026-09-03T20:29:39.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":12500,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0002050167-26-000025","document":"form4-09032026_080935.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000025/form4-09032026_080935.xml","form_type":"4"}},{"id":2425,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-09-03T20:29:39.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":38750,"source":{"system":"sec-edgar","filing":"0002050167-26-000025","document":"form4-09032026_080935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000025/form4-09032026_080935.xml","form_type":"4"}},{"id":2363,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-09-03T20:27:42.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001676170-26-000020","document":"form4-09032026_080937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000020/form4-09032026_080937.xml","form_type":"4"}},{"id":2362,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:27:42.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001676170-26-000020","document":"form4-09032026_080937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000020/form4-09032026_080937.xml","form_type":"4"}},{"id":2361,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:27:42.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":31908,"price":26.2876,"value":838784.7408,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.13 to $26.555 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":223355,"source":{"system":"sec-edgar","filing":"0001676170-26-000020","document":"form4-09032026_080937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000020/form4-09032026_080937.xml","form_type":"4"}},{"id":2360,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:27:42.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":2593,"price":26.307,"value":68214.051,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.50 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":18151,"source":{"system":"sec-edgar","filing":"0001676170-26-000020","document":"form4-09032026_080937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000167617026000020/form4-09032026_080937.xml","form_type":"4"}},{"id":2315,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2314,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":16141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":160662,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":16141},"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2313,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2312,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":16141,"price":26.3622,"value":425512.2702,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":2311,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-09-03T20:24:01.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":16141,"price":10.42,"value":168189.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":16141,"source":{"system":"sec-edgar","filing":"0002050172-26-000032","document":"form4-09032026_080957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000032/form4-09032026_080957.xml","form_type":"4"}},{"id":672184,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-31T22:32:29.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025."}],"balance_after":14143,"derivative":{"exercise_price":10.42,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0002050167-26-000023","document":"form4-08312026_100823.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000023/form4-08312026_100823.xml","form_type":"4"}},{"id":672183,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-08-31T22:32:29.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":27.5765,"value":206823.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $28.01 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":26250,"source":{"system":"sec-edgar","filing":"0002050167-26-000023","document":"form4-08312026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000023/form4-08312026_100823.xml","form_type":"4"}},{"id":672182,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-08-31T22:32:29.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":10.42,"value":78150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":33750,"source":{"system":"sec-edgar","filing":"0002050167-26-000023","document":"form4-08312026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000023/form4-08312026_100823.xml","form_type":"4"}},{"id":685039,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":22737,"kind":"person","name":"Kornowski Sophie","position":1,"cik":"0001894117","reported_name":"Kornowski Sophie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T20:52:24.000Z","date":"2026-08-13","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":36000,"derivative":{"exercise_price":27.665,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001894117-26-000006","document":"form4-08172026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1842295/000189411726000006/form4-08172026_080820.xml","form_type":"4"}},{"id":685285,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":10923,"kind":"person","name":"Johnson Paula A","position":1,"cik":"0001341161","reported_name":"Johnson Paula A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T20:51:08.000Z","date":"2026-08-13","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":36000,"derivative":{"exercise_price":27.665,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001341161-26-000005","document":"form4-08172026_080804.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341161/000134116126000005/form4-08172026_080804.xml","form_type":"4"}},{"id":687113,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:54:48.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":false,"shares":16142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":176803,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":16142},"source":{"system":"sec-edgar","filing":"0002050172-26-000028","document":"form4-08142026_080845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000028/form4-08142026_080845.xml","form_type":"4"}},{"id":687112,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:48.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":16142,"price":27.6063,"value":445620.8946,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $28.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000028","document":"form4-08142026_080845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000028/form4-08142026_080845.xml","form_type":"4"}},{"id":687111,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:48.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":true,"shares":16142,"price":10.42,"value":168199.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":16142,"source":{"system":"sec-edgar","filing":"0002050172-26-000028","document":"form4-08142026_080845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000028/form4-08142026_080845.xml","form_type":"4"}},{"id":695256,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-05T20:08:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1604,"price":27.0853,"value":43444.8212,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.19 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":255263,"source":{"system":"sec-edgar","filing":"0001676170-26-000016","document":"form4-08052026_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000016/form4-08052026_080854.xml","form_type":"4"}},{"id":695255,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-05T20:08:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":30304,"price":26.714,"value":809541.056,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.005 to $26.985 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":256867,"source":{"system":"sec-edgar","filing":"0001676170-26-000016","document":"form4-08052026_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000016/form4-08052026_080854.xml","form_type":"4"}},{"id":695254,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-05T20:08:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":154,"price":27.094,"value":4172.476,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.16 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":20744,"source":{"system":"sec-edgar","filing":"0001676170-26-000016","document":"form4-08052026_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000016/form4-08052026_080854.xml","form_type":"4"}},{"id":695253,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-05T20:08:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":2439,"price":26.7145,"value":65156.6655,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.97 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4, 5, and 7 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees."}],"balance_after":20898,"source":{"system":"sec-edgar","filing":"0001676170-26-000016","document":"form4-08052026_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000016/form4-08052026_080854.xml","form_type":"4"}},{"id":700103,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-31T20:15:20.000Z","date":"2026-07-29","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025."}],"balance_after":21643,"derivative":{"exercise_price":10.42,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0002050167-26-000019","document":"form4-07312026_080715.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000019/form4-07312026_080715.xml","form_type":"4"}},{"id":700102,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-07-31T20:15:20.000Z","date":"2026-07-29","kind":"sale","planned":true,"acquired":false,"shares":400,"price":27.89,"value":11156.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.81 to $27.96 per share, inclusive."}],"balance_after":26250,"source":{"system":"sec-edgar","filing":"0002050167-26-000019","document":"form4-07312026_080715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000019/form4-07312026_080715.xml","form_type":"4"}},{"id":700101,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-07-31T20:15:20.000Z","date":"2026-07-29","kind":"sale","planned":true,"acquired":false,"shares":7100,"price":27.3064,"value":193875.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $27.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":26650,"source":{"system":"sec-edgar","filing":"0002050167-26-000019","document":"form4-07312026_080715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000019/form4-07312026_080715.xml","form_type":"4"}},{"id":700100,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-07-31T20:15:20.000Z","date":"2026-07-29","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":10.42,"value":78150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":33750,"source":{"system":"sec-edgar","filing":"0002050167-26-000019","document":"form4-07312026_080715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000019/form4-07312026_080715.xml","form_type":"4"}},{"id":718673,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":14609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":192945,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":14609},"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":718672,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1200,"price":30.3369,"value":36404.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.24 to $30.42 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":718671,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":13409,"price":29.865,"value":400459.785,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.24 to $30.23 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":1200,"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":718670,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-07-02T20:29:57.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":14609,"price":10.42,"value":152225.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":14609,"source":{"system":"sec-edgar","filing":"0002050172-26-000025","document":"form4-07022026_080753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000025/form4-07022026_080753.xml","form_type":"4"}},{"id":717128,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:28:41.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1597,"price":30.4359,"value":48606.1323,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.385 to $30.49 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":287171,"source":{"system":"sec-edgar","filing":"0001676170-26-000014","document":"form4-07022026_080737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000014/form4-07022026_080737.xml","form_type":"4"}},{"id":717127,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:28:41.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":30311,"price":29.9535,"value":907920.5385,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.375 to $30.37 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":288768,"source":{"system":"sec-edgar","filing":"0001676170-26-000014","document":"form4-07022026_080737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000014/form4-07022026_080737.xml","form_type":"4"}},{"id":717126,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:28:41.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":2593,"price":29.9754,"value":77726.2122,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.455 to $30.38 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 and 6 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust (the \"Irrevocable Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":23337,"source":{"system":"sec-edgar","filing":"0001676170-26-000014","document":"form4-07022026_080737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000014/form4-07022026_080737.xml","form_type":"4"}},{"id":721601,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:17:19.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025."}],"balance_after":29143,"derivative":{"exercise_price":10.42,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0002050167-26-000016","document":"form4-07012026_080715.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000016/form4-07012026_080715.xml","form_type":"4"}},{"id":721600,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-07-01T20:17:19.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":28.02,"value":210150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":26250,"source":{"system":"sec-edgar","filing":"0002050167-26-000016","document":"form4-07012026_080715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000016/form4-07012026_080715.xml","form_type":"4"}},{"id":721599,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-07-01T20:17:19.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":10.42,"value":78150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported total includes 1,442 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c)."}],"balance_after":33750,"source":{"system":"sec-edgar","filing":"0002050167-26-000016","document":"form4-07012026_080715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000016/form4-07012026_080715.xml","form_type":"4"}},{"id":727386,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-24T20:14:54.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":23865,"price":26.0496,"value":621673.704,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.185 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":319079,"source":{"system":"sec-edgar","filing":"0001676170-26-000012","document":"form4-06242026_080649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000012/form4-06242026_080649.xml","form_type":"4"}},{"id":727385,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-24T20:14:54.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":2040,"price":26,"value":53040.0,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust (the \"Irrevocable Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":25930,"source":{"system":"sec-edgar","filing":"0001676170-26-000012","document":"form4-06242026_080649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000012/form4-06242026_080649.xml","form_type":"4"}},{"id":727384,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-24T20:14:54.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":1953,"price":26.0015,"value":50780.9295,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.025 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":342944,"source":{"system":"sec-edgar","filing":"0001676170-26-000012","document":"form4-06242026_080649.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000012/form4-06242026_080649.xml","form_type":"4"}},{"id":742935,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:31:33.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001238403-26-000004","document":"form4-06102026_080629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000123840326000004/form4-06102026_080629.xml","form_type":"4"}},{"id":742898,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":37180,"kind":"person","name":"SCHELLER RICHARD H","position":1,"cik":"0001214133","reported_name":"SCHELLER RICHARD H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:30:06.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001214133-26-000002","document":"form4-06102026_080600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214133/000121413326000002/form4-06102026_080600.xml","form_type":"4"}},{"id":742956,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":38112,"kind":"person","name":"Lim Jonathan E","position":1,"cik":"0001283290","reported_name":"Lim Jonathan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:28:22.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001283290-26-000002","document":"form4-06102026_080618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1283290/000128329026000002/form4-06102026_080618.xml","form_type":"4"}},{"id":742687,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":39558,"kind":"person","name":"Hoppenot Herve","position":1,"cik":"0001596492","reported_name":"Hoppenot Herve","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:26:54.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001596492-26-000007","document":"form4-06102026_080650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1596492/000159649226000007/form4-06102026_080650.xml","form_type":"4"}},{"id":742907,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:25:30.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001192591-26-000004","document":"form4-06102026_080626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000119259126000004/form4-06102026_080626.xml","form_type":"4"}},{"id":743247,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":21332,"kind":"person","name":"Andrews Nancy C","position":1,"cik":"0001804999","reported_name":"Andrews Nancy C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:23:47.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.58,"expiration_date":"2036-06-07","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001804999-26-000002","document":"form4-06102026_080643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804999/000180499926000002/form4-06102026_080643.xml","form_type":"4"}},{"id":750782,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-03T21:04:16.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":553,"price":26.2412,"value":14511.3836,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.50 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust (the \"Irrevocable Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":27970,"source":{"system":"sec-edgar","filing":"0001676170-26-000009","document":"form4-06032026_090612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000009/form4-06032026_090612.xml","form_type":"4"}},{"id":750781,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-03T21:04:16.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":6090,"price":26.1965,"value":159536.685,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.545 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":344897,"source":{"system":"sec-edgar","filing":"0001676170-26-000009","document":"form4-06032026_090612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000009/form4-06032026_090612.xml","form_type":"4"}},{"id":752358,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":14853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":207554,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":14853},"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":752357,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":26.3576,"value":42172.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":752356,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":13253,"price":25.5746,"value":338940.1738,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":1600,"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":752355,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-06-03T21:01:37.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":14853,"price":10.42,"value":154768.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":14853,"source":{"system":"sec-edgar","filing":"0002050172-26-000023","document":"form4-06032026_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000023/form4-06032026_090633.xml","form_type":"4"}},{"id":755339,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T20:12:07.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025."}],"balance_after":36643,"derivative":{"exercise_price":10.42,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0002050167-26-000013","document":"form4-06022026_080603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000013/form4-06022026_080603.xml","form_type":"4"}},{"id":755338,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-06-02T20:12:07.000Z","date":"2026-05-29","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":26.3405,"value":197553.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":24808,"source":{"system":"sec-edgar","filing":"0002050167-26-000013","document":"form4-06022026_080603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000013/form4-06022026_080603.xml","form_type":"4"}},{"id":755337,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-06-02T20:12:07.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":10.42,"value":78150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":32308,"source":{"system":"sec-edgar","filing":"0002050167-26-000013","document":"form4-06022026_080603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000013/form4-06022026_080603.xml","form_type":"4"}},{"id":761225,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:16:23.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":25582,"price":26.015,"value":665515.73,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.09 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":350987,"source":{"system":"sec-edgar","filing":"0001676170-26-000007","document":"form4-05272026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000007/form4-05272026_080518.xml","form_type":"4"}},{"id":761224,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:16:23.000Z","date":"2026-05-22","kind":"sale","planned":true,"acquired":false,"shares":2478,"price":26,"value":64428.0,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust (the \"Irrevocable Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":28523,"source":{"system":"sec-edgar","filing":"0001676170-26-000007","document":"form4-05272026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000007/form4-05272026_080518.xml","form_type":"4"}},{"id":761223,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:16:23.000Z","date":"2026-05-22","kind":"sale","planned":true,"acquired":false,"shares":4504,"price":26.0001,"value":117104.4504,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.105 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":376569,"source":{"system":"sec-edgar","filing":"0001676170-26-000007","document":"form4-05272026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000007/form4-05272026_080518.xml","form_type":"4"}},{"id":774300,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-18T21:07:29.000Z","date":"2026-05-15","kind":"sale","planned":true,"acquired":false,"shares":116,"price":26,"value":3016.0,"ownership":{"direct":false,"nature":"The Coloma 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are directly held by The Coloma 2021 Irrevocable Trust (the \"Irrevocable Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":31001,"source":{"system":"sec-edgar","filing":"0001676170-26-000004","document":"form4-05182026_090526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000004/form4-05182026_090526.xml","form_type":"4"}},{"id":774299,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1793,"kind":"person","name":"Coloma Jason V","position":1,"cik":"0001676170","reported_name":"Coloma Jason V","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-18T21:07:29.000Z","date":"2026-05-15","kind":"sale","planned":true,"acquired":false,"shares":1822,"price":26,"value":47372.0,"ownership":{"direct":false,"nature":"Coloma Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by the Coloma Family Trust (the \"Family Trust\"), for which the reporting person and his spouse serve as co-trustees."}],"balance_after":381073,"source":{"system":"sec-edgar","filing":"0001676170-26-000004","document":"form4-05182026_090526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676170/000167617026000004/form4-05182026_090526.xml","form_type":"4"}},{"id":775436,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T21:03:49.000Z","date":"2026-05-14","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":222407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002050172-26-000021","document":"form4-05182026_090546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000021/form4-05182026_090546.xml","form_type":"4"}},{"id":775435,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-05-18T21:03:49.000Z","date":"2026-05-14","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":26.2236,"value":393354.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.44 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000021","document":"form4-05182026_090546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000021/form4-05182026_090546.xml","form_type":"4"}},{"id":775434,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-05-18T21:03:49.000Z","date":"2026-05-14","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":10.42,"value":156300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0002050172-26-000021","document":"form4-05182026_090546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000021/form4-05182026_090546.xml","form_type":"4"}},{"id":790159,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-06T20:15:49.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":5985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":27725,"derivative":{"exercise_price":10.42,"expiration_date":"2033-03-03","underlying":"Common Stock","underlying_shares":5985},"source":{"system":"sec-edgar","filing":"0002050167-26-000010","document":"form4-05062026_080545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000010/form4-05062026_080545.xml","form_type":"4"}},{"id":790158,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-06T20:15:49.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":8320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026."}],"balance_after":20204,"derivative":{"exercise_price":10.42,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":8320},"source":{"system":"sec-edgar","filing":"0002050167-26-000010","document":"form4-05062026_080545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000010/form4-05062026_080545.xml","form_type":"4"}},{"id":790157,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-05-06T20:15:49.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":5985,"price":10.42,"value":62363.7,"ownership":{"direct":true},"balance_after":24808,"source":{"system":"sec-edgar","filing":"0002050167-26-000010","document":"form4-05062026_080545.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000010/form4-05062026_080545.xml","form_type":"4"}},{"id":790156,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-05-06T20:15:49.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":8320,"price":10.42,"value":86694.4,"ownership":{"direct":true},"balance_after":18823,"source":{"system":"sec-edgar","filing":"0002050167-26-000010","document":"form4-05062026_080545.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000010/form4-05062026_080545.xml","form_type":"4"}},{"id":789637,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T20:13:06.000Z","date":"2026-05-04","kind":"gift","planned":false,"acquired":false,"shares":7422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total reflected in Column 5 of Table I includes shares which were previously held directly by the Charles J. Homcy Revocable Trust UA 11/4/1998."}],"balance_after":31113,"source":{"system":"sec-edgar","filing":"0001192591-26-000002","document":"form4-05062026_080559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192591/000119259126000002/form4-05062026_080559.xml","form_type":"4"}},{"id":795946,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-01T20:18:22.000Z","date":"2026-04-29","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025."}],"balance_after":44143,"derivative":{"exercise_price":10.42,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0002050167-26-000008","document":"form4-05012026_080517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000008/form4-05012026_080517.xml","form_type":"4"}},{"id":795945,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-05-01T20:18:22.000Z","date":"2026-04-29","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":25.3732,"value":190299.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.08 to $25.77 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10503,"source":{"system":"sec-edgar","filing":"0002050167-26-000008","document":"form4-05012026_080517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000008/form4-05012026_080517.xml","form_type":"4"}},{"id":795944,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1840,"kind":"person","name":"Dandekar Atul","position":1,"cik":"0002050167","reported_name":"Dandekar Atul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSBO"}}],"security":"Common Stock","published_at":"2026-05-01T20:18:22.000Z","date":"2026-04-29","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":10.42,"value":78150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":18003,"source":{"system":"sec-edgar","filing":"0002050167-26-000008","document":"form4-05012026_080517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050167/000205016726000008/form4-05012026_080517.xml","form_type":"4"}},{"id":820383,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T20:08:21.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":237407,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0002050172-26-000019","document":"form4-04022026_080416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000019/form4-04022026_080416.xml","form_type":"4"}},{"id":820382,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":1776,"kind":"person","name":"Bernstein Harold","position":1,"cik":"0002050172","reported_name":"Bernstein Harold","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2026-04-02T20:08:21.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":300,"price":31.0667,"value":9320.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.80 to $31.22 per share, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002050172-26-000019","document":"form4-04022026_080416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050172/000205017226000019/form4-04022026_080416.xml","form_type":"4"}}],"next_cursor":"2026-04-02T20:08:21.000000Z,820382"}